Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Insights into microbiome research 1: How to choose appropriate controls for a microbiome study in MS?

Baranzini SE.

Mult Scler. 2018 Sep;24(10):1278-1279. doi: 10.1177/1352458518788967.

PMID:
30129894
2.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

PMID:
29908077
3.

Correction: Peroxisome proliferator-activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.

Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, Crowell A, Loh J, Oksenberg J, Steinman L.

J Exp Med. 2018 Jun 4;215(6):1765. doi: 10.1084/jem.2006183905142018c. Epub 2018 May 17. No abstract available.

4.

Multiple sclerosis.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O.

Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23. Review.

PMID:
29576504
5.

The microbiome and MS: The influence of the microbiota on MS risk and progression-Session chair summary.

Sand IK, Baranzini SE.

Mult Scler. 2018 Apr;24(5):587-589. doi: 10.1177/1352458518761167. Epub 2018 Mar 2. No abstract available.

PMID:
29498302
6.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407. [Epub ahead of print]

PMID:
29310490
7.

The Gut Microbiome in Neuromyelitis Optica.

Zamvil SS, Spencer CM, Baranzini SE, Cree BAC.

Neurotherapeutics. 2018 Jan;15(1):92-101. doi: 10.1007/s13311-017-0594-z. Review.

8.

The era of GWAS is over - Commentary.

Baranzini SE.

Mult Scler. 2018 Mar;24(3):260-261. doi: 10.1177/1352458517747408. Epub 2017 Dec 18. No abstract available.

PMID:
29251183
9.

The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".

Pröbstel AK, Baranzini SE.

Neurotherapeutics. 2018 Jan;15(1):126-134. doi: 10.1007/s13311-017-0587-y. Review.

PMID:
29147991
10.

The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years.

Baranzini SE, Oksenberg JR.

Trends Genet. 2017 Dec;33(12):960-970. doi: 10.1016/j.tig.2017.09.004. Epub 2017 Oct 5. Review.

PMID:
28987266
11.

Systematic integration of biomedical knowledge prioritizes drugs for repurposing.

Himmelstein DS, Lizee A, Hessler C, Brueggeman L, Chen SL, Hadley D, Green A, Khankhanian P, Baranzini SE.

Elife. 2017 Sep 22;6. pii: e26726. doi: 10.7554/eLife.26726.

12.

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.

Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, Kümpfel T, Hohlfeld R, Krishnamoorthy G, Wekerle H.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.

13.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

14.

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis.

Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR.

Data Brief. 2017 Feb 21;11:364-370. doi: 10.1016/j.dib.2017.02.040. eCollection 2017 Apr.

15.

The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis.

Fewings NL, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR.

J Autoimmun. 2017 Mar;78:57-69. doi: 10.1016/j.jaut.2016.12.006. Epub 2017 Jan 4.

PMID:
28063629
16.

Immune cell-specific transcriptional profiling highlights distinct molecular pathways controlled by Tob1 upon experimental autoimmune encephalomyelitis.

Didonna A, Cekanaviciute E, Oksenberg JR, Baranzini SE.

Sci Rep. 2016 Aug 22;6:31603. doi: 10.1038/srep31603.

17.

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS.

Ann Neurol. 2016 Sep;80(3):443-7. doi: 10.1002/ana.24718. Epub 2016 Aug 4.

18.

Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, Caillier SJ, Santaniello A, Lizée A, Himmelstein DS, Baranzini SE, Hollenbach J, Cree BA, Hauser SL, Oksenberg JR, Henry RG.

JAMA Neurol. 2016 Jul 1;73(7):795-802. doi: 10.1001/jamaneurol.2016.0980.

19.

Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.

Khankhanian P, Cozen W, Himmelstein DS, Madireddy L, Din L, van den Berg A, Matsushita T, Glaser SL, Moré JM, Smedby KE, Baranzini SE, Mack TM, Lizée A, de Sanjosé S, Gourraud PA, Nieters A, Hauser SL, Cocco P, Maynadié M, Foretová L, Staines A, Delahaye-Sourdeix M, Li D, Bhatia S, Melbye M, Onel K, Jarrett R, McKay JD, Oksenberg JR, Hjalgrim H.

Int J Epidemiol. 2016 Jun;45(3):728-40. doi: 10.1093/ije/dyv364. Epub 2016 Mar 12.

20.

iCTNet2: integrating heterogeneous biological interactions to understand complex traits.

Wang L, Himmelstein DS, Santaniello A, Parvin M, Baranzini SE.

Version 2. F1000Res. 2015 Aug 5 [revised 2015 Jan 1];4:485. doi: 10.12688/f1000research.6836.2. eCollection 2015.

21.

Assessing the Power of Exome Chips.

Page CM, Baranzini SE, Mevik BH, Bos SD, Harbo HF, Andreassen BK.

PLoS One. 2015 Oct 5;10(10):e0139642. doi: 10.1371/journal.pone.0139642. eCollection 2015.

22.

A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome.

Didonna A, Isobe N, Caillier SJ, Li KH, Burlingame AL, Hauser SL, Baranzini SE, Patsopoulos NA, Oksenberg JR.

Hum Mol Genet. 2015 Dec 15;24(24):7151-8. doi: 10.1093/hmg/ddv412. Epub 2015 Oct 3.

23.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

24.

Genetic contribution to multiple sclerosis risk among Ashkenazi Jews.

Khankhanian P, Matsushita T, Madireddy L, Lizée A, Din L, Moré JM, Gourraud PA, Hauser SL, Baranzini SE, Oksenberg JR.

BMC Med Genet. 2015 Jul 28;16:55. doi: 10.1186/s12881-015-0201-2.

25.

Heterogeneous Network Edge Prediction: A Data Integration Approach to Prioritize Disease-Associated Genes.

Himmelstein DS, Baranzini SE.

PLoS Comput Biol. 2015 Jul 9;11(7):e1004259. doi: 10.1371/journal.pcbi.1004259. eCollection 2015 Jul.

26.

A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.

Harari D, Orr I, Rotkopf R, Baranzini SE, Schreiber G.

Hum Mol Genet. 2015 Jun 1;24(11):3192-205. doi: 10.1093/hmg/ddv071. Epub 2015 Feb 26.

PMID:
25721402
27.

SNP imputation bias reduces effect size determination.

Khankhanian P, Din L, Caillier SJ, Gourraud PA, Baranzini SE.

Front Genet. 2015 Feb 9;6:30. doi: 10.3389/fgene.2015.00030. eCollection 2015.

28.

Genetic associations with brain cortical thickness in multiple sclerosis.

Matsushita T, Madireddy L, Sprenger T, Khankhanian P, Magon S, Naegelin Y, Caverzasi E, Lindberg RL, Kappos L, Hauser SL, Oksenberg JR, Henry R, Pelletier D, Baranzini SE.

Genes Brain Behav. 2015 Feb;14(2):217-27. doi: 10.1111/gbb.12190. Epub 2015 Mar 5.

29.

Whole genome sequences of 2 octogenarians with sustained cognitive abilities.

Nickles D, Madireddy L, Patel N, Isobe N, Miller BL, Baranzini SE, Kramer JH, Oksenberg JR.

Neurobiol Aging. 2015 Mar;36(3):1435-8. doi: 10.1016/j.neurobiolaging.2014.11.003. Epub 2014 Dec 16.

30.
31.

Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis.

Haghikia A, Faissner S, Pappas D, Pula B, Akkad DA, Arning L, Ruhrmann S, Duscha A, Gold R, Baranzini SE, Malhotra S, Montalban X, Comabella M, Chan A.

Mult Scler. 2015 Sep;21(10):1262-70. doi: 10.1177/1352458514561909. Epub 2014 Dec 5.

PMID:
25480861
32.

Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.

Baranzini SE, Madireddy LR, Cromer A, D'Antonio M, Lehr L, Beelke M, Farmer P, Battaglini M, Caillier SJ, Stromillo ML, De Stefano N, Monnet E, Cree BA.

Mult Scler. 2015 Jun;21(7):894-904. doi: 10.1177/1352458514555786. Epub 2014 Nov 12.

33.
34.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

35.

PINBPA: cytoscape app for network analysis of GWAS data.

Wang L, Matsushita T, Madireddy L, Mousavi P, Baranzini SE.

Bioinformatics. 2015 Jan 15;31(2):262-4. doi: 10.1093/bioinformatics/btu644. Epub 2014 Sep 25.

PMID:
25260698
36.

The role of antiproliferative gene Tob1 in the immune system.

Baranzini SE.

Clin Exp Neuroimmunol. 2014 Jun 1;5(2):132-136.

37.

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC.

J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.

38.

Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.

Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.

Mult Scler. 2014 Dec;20(14):1851-9. doi: 10.1177/1352458514534513. Epub 2014 May 22.

PMID:
24852919
39.

Astrocyte-encoded positional cues maintain sensorimotor circuit integrity.

Molofsky AV, Kelley KW, Tsai HH, Redmond SA, Chang SM, Madireddy L, Chan JR, Baranzini SE, Ullian EM, Rowitch DH.

Nature. 2014 May 8;509(7499):189-94. doi: 10.1038/nature13161. Epub 2014 Apr 28.

40.

Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer.

Fancy SP, Harrington EP, Baranzini SE, Silbereis JC, Shiow LR, Yuen TJ, Huang EJ, Lomvardas S, Rowitch DH.

Nat Neurosci. 2014 Apr;17(4):506-12. doi: 10.1038/nn.3676. Epub 2014 Mar 9. Erratum in: Nat Neurosci. 2014 Dec;17(12):1841.

41.

A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility.

Damotte V, Guillot-Noel L, Patsopoulos NA, Madireddy L, El Behi M; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, De Jager PL, Baranzini SE, Cournu-Rebeix I, Fontaine B.

Genes Immun. 2014 Mar;15(2):126-32. doi: 10.1038/gene.2013.70. Epub 2014 Jan 16.

42.

Sequencing of the IL6 gene in a case-control study of cerebral palsy in children.

Khankhanian P, Baranzini SE, Johnson BA, Madireddy L, Nickles D, Croen LA, Wu YW.

BMC Med Genet. 2013 Dec 7;14:126. doi: 10.1186/1471-2350-14-126.

43.

Gene expression profiling in MS: a fulfilled promise?

Baranzini SE.

Mult Scler. 2013 Dec;19(14):1813-4. doi: 10.1177/1352458513501573. No abstract available.

PMID:
24277731
44.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

45.

Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis.

Rossi S, Studer V, Moscatelli A, Motta C, Coghe G, Fenu G, Caillier S, Buttari F, Mori F, Barbieri F, Castelli M, De Chiara V, Monteleone F, Mancino R, Bernardi G, Baranzini SE, Marrosu MG, Oksenberg JR, Centonze D.

PLoS One. 2013 Jun 28;8(6):e67357. doi: 10.1371/journal.pone.0067357. Print 2013.

46.

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.

Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE.

J Exp Med. 2013 Jul 1;210(7):1301-9.

47.

Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls.

Nickles D, Chen HP, Li MM, Khankhanian P, Madireddy L, Caillier SJ, Santaniello A, Cree BA, Pelletier D, Hauser SL, Oksenberg JR, Baranzini SE.

Hum Mol Genet. 2013 Oct 15;22(20):4194-205. doi: 10.1093/hmg/ddt267. Epub 2013 Jun 6.

48.

Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors.

Dutta R, Chomyk AM, Chang A, Ribaudo MV, Deckard SA, Doud MK, Edberg DD, Bai B, Li M, Baranzini SE, Fox RJ, Staugaitis SM, Macklin WB, Trapp BD.

Ann Neurol. 2013 May;73(5):637-45. doi: 10.1002/ana.23860. Epub 2013 Apr 17.

49.

A genome-wide association study of brain lesion distribution in multiple sclerosis.

Gourraud PA, Sdika M, Khankhanian P, Henry RG, Beheshtian A, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D, Baranzini SE.

Brain. 2013 Apr;136(Pt 4):1012-24. doi: 10.1093/brain/aws363. Epub 2013 Feb 13.

50.

Transcriptional expression patterns triggered by chemically distinct neuroprotective molecules.

Pappas DJ, Gabatto PA, Oksenberg D, Khankhanian P, Baranzini SE, Gan L, Oksenberg JR.

Neuroscience. 2012 Dec 13;226:10-20. doi: 10.1016/j.neuroscience.2012.09.007. Epub 2012 Sep 15.

Supplemental Content

Loading ...
Support Center